AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 25384996
Drug: Respiratory-gated strategy
RxNorm normalized name: tissue respiratory factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Respiratory-gated strategy with 4-dimensional CT treatment planning
Trial: 30062746
Drug: Opioid dose
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid dose
Trial: 19858764
Drug: Estrogen +
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen + progestin therapy
Trial: 16262020
Drug: Metronidazole (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole (200 mg 3 times daily for 7 days) and cephalexin (500 mg twice daily for 5 days)
Trial: 10221237
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg vitamin C and 800 mg vitamin E (n = 15)
Trial: 10221237
Drug: Identical placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical placebo capsules (n = 16)
Trial: 1702048
Drug: Insulin and
RxNorm normalized name: Isophane insulin and porcine regular insulin only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin and glucagon (treatment group)
Trial: 6342955
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg tilcotil (Ro12-0068) once daily for 2 weeks
Trial: 6342955
Drug: 900 mg
RxNorm normalized name: diosmin 900 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900 mg enteric-coated aspirin 4 times daily for 2 weeks
Trial: 31710306
Drug: Oral Health
RxNorm normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Health Text messages (OHT)
Trial: 19486267
Drug: Intralesional BCG-PSN
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional BCG-PSN injection (0.5 ml every other day for 2 weeks)
Trial: 19486267
Drug: Triamcinolone acetonide
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triamcinolone acetonide (10 mg every week for 2 weeks)
Trial: 19486267
Drug: Intralesional BCG-PSN
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional BCG-PSN injection
Trial: 11606340
Drug: IM droperidol
RxNorm normalized name: Droperidol
DrugBank: Droperidol (DB00450)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IM droperidol 0.1 mg x kg(‐1) 30 min before anesthesia
Trial: 9116924
Drug: losartan 50
RxNorm normalized name: LOSARTAN 50MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: losartan 50 mg titrated to 100 mg
Trial: 2667265
Drug: Coenzyme Q10
RxNorm normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Coenzyme Q10 (ubiquinone) 3x 33.3 mg per day, orally for four months
Trial: 31825192
Drug: Trastuzumab deruxtecan
RxNorm normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab deruxtecan (5.4 mg/kg)
Trial: 24280596
Drug: Statin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin plus ezetimibe 10 mg daily
Trial: 24280596
Drug: Statin uptitration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin uptitration (double doses of statin)
Trial: 22109255
Drug: varespladib methyl
RxNorm normalized name: Varespladib methyl
DrugBank: Varespladib methyl (DB05737)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: varespladib methyl 500 mg daily
Trial: 19445545
Drug: Multimodal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal treatment (psychopharmacologic treatment combined with psychosocial interventions)
Trial: 14506491
Drug: Usual nephropathy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual nephropathy diet (0.8 g/kg protein, 70% animal and 30% vegetable protein)
Trial: 10981570
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine (160 microg in 4 ml normal saline)
Trial: 10981570
Drug: Intrathecal nalbuphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal nalbuphine (400 microg in 4 ml normal saline)
Trial: 3709028
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg oral and intravenous doses of bumetanide (CRF group)
Trial: 3709028
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg oral and intravenous doses of bumetanide (HS group)
Trial: 24336090
Drug: Teacher-led daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teacher-led daily 10-minute stress management intervention for 4 months
Trial: 24336090
Drug: Control class
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control class (reading from a children's book for 10 minutes daily)
Trial: 2093126
Drug: Propranolol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (10 mg) with Quinidine (100 mg)
Trial: 2093126
Drug: Propranolol (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (20 mg) with Quinidine (200 mg)
Trial: 21680059
Drug: High-flow oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-flow oxygen (100% oxygen at 15 L/minute by nonrebreather mask for 5 minutes before and during sedation)
Trial: 21680059
Drug: Compressed air
RxNorm normalized name: air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compressed air (15 L/minute by nonrebreather mask for 5 minutes before and during sedation)
Trial: 24622243
Drug: sST2 <33.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sST2 <33.2 ng/mL
Trial: 24032185
Drug: Conventional acupuncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional acupuncture and massage therapy
Trial: 18835318
Drug: 2-dose recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-dose recombinant vaccine
Trial: 18835318
Drug: 3-dose recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-dose recombinant vaccine
Trial: 18835318
Drug: 3-dose plasma-derived
RxNorm normalized name: c1-inhibitor, plasma derived
DrugBank: Human C1-esterase inhibitor (DB06404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-dose plasma-derived vaccine
Trial: 15297847
Drug: Thalidomide plus
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Thalidomide plus oral melphalan (TM group)
Trial: 8345035
Drug: CGS 20267
RxNorm normalized name: Alkamide 101-cg
DrugBank: Coco diethanolamide (DB18828)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CGS 20267 (0.1 mg)
Trial: 8345035
Drug: CGS 20267
RxNorm normalized name: Alkamide 101-cg
DrugBank: Coco diethanolamide (DB18828)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CGS 20267 (0.5 mg)
Trial: 8345035
Drug: CGS 20267
RxNorm normalized name: Alkamide 101-cg
DrugBank: Coco diethanolamide (DB18828)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CGS 20267 (2.5 mg)
Trial: 31027435
Drug: AMPH EROS
RxNorm normalized name: AMPH-b
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AMPH EROS 18.8 mg under fed conditions
Trial: 31027435
Drug: AMPH EROS
RxNorm normalized name: AMPH-b
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AMPH EROS 18.8 mg under fasted conditions
Trial: 31027435
Drug: IR MAS
RxNorm normalized name: SALICYLIC ACID 20 mg in 1 mL TOPICAL CREAM [Dandruff Repair Mask]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IR MAS 30 mg under fasted conditions
Trial: 25250647
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 600 mg intravenous, administered 1 hr before and 2 hr after cerebral angiography.
Trial: 19165664
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist (triptorelin 0.2 mg, n = 106)
Trial: 14762743
Drug: Closed treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Closed treatment without surgical reduction (n = 44)
Trial: 2884706
Drug: Broxaterol 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Broxaterol 0.5 mg
Trial: 2884706
Drug: Salbutamol 4.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol 4.0 mg
Trial: 26793956
Drug: Continued thienopyridine
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued thienopyridine plus aspirin
Trial: 16450594
Drug: Prophylactic intravenous
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic intravenous lidocaine 1 mg/kg
Trial: 16450594
Drug: Therapeutic intravenous
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic intravenous lidocaine 0.5 mg/kg
Trial: 10569330
Drug: HPMC 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPMC 2.5 g/day
Trial: 10569330
Drug: HPMC 5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPMC 5.0 g/day
Trial: 10569330
Drug: HPMC 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPMC 7.5 g/day
Trial: 6313522
Drug: twice-daily placebo
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: twice-daily placebo (n = 77)
Trial: 6313522
Drug: twice-daily captopril
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: twice-daily captopril 25 mg (n = 77)
Trial: 6313522
Drug: twice-daily captopril
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: twice-daily captopril 50 mg (n = 71)
Trial: 6313522
Drug: twice-daily captopril
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: twice-daily captopril 100 mg (n = 69)
Trial: 30924570
Drug: Low carbohydrate
RxNorm normalized name: Low carbohydrate beer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low carbohydrate diet (LCD < 100 g carbohydrate/d)
Trial: 30924570
Drug: High carbohydrate
RxNorm normalized name: High carbohydrate food
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High carbohydrate diet (HCD > 250 g carbohydrate/d)
Trial: 30217492
Drug: Nonprotocol therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonprotocol therapy
Trial: 27535063
Drug: Combined oral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined oral contraceptives (COCs) containing 30μg ethinylestradiol (EE) and 3mg drospirenone (DRSP) in a 21/7 regimen
Trial: 22963592
Drug: Nonblind clinician
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonblind clinician and patient ratings of treatment response
Trial: 21526664
Drug: Fentanyl pretreatment
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl pretreatment (1 microg/kg diluted in saline to a volume of 5 ml)
Trial: 21526664
Drug: Placebo (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (5 ml normal saline)
Trial: 17693179
Drug: Sapropterin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sapropterin (10 mg/kg, oral, once daily for 6 weeks)
Trial: 17693179
Drug: Placebo (oral,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (oral, once daily for 6 weeks)
Trial: 10323379
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose GH treatment (66 or 100 microg/kg x day s.c. over 2 years)
Trial: 10323379
Drug: Second course
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Second course of GH treatment (66 microg/kg x day s.c.)
Trial: 10323379
Drug: No further
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No further GH treatment after initial GH withdrawal (mean adjusted height SD score -2.7, n = 13)
Trial: 10323379
Drug: No further
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No further GH treatment after initial GH withdrawal (mean adjusted height -3.3 SD score, n = 9)
Trial: 6120705
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg of midazolam (Ro 21‐3981, Dormicum) administered p.o.
Trial: 6120705
Drug: 7 mg
RxNorm normalized name: pectin 7 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 mg of oxazepam administered p.o.
Trial: 19915080
Drug: 4 individualized
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4 individualized counselor-led MI sessions and nicotine replacement therapy (NRT)
Trial: 15506574
Drug: Pen-tablet computers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pen-tablet computers for data collection
Trial: 16325299
Drug: Insulin infusion
RxNorm normalized name: iLet Insulin Infusion 10-Pack Kit Inset
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin infusion algorithm
Trial: 1804386
Drug: 5-fluorouracil-leucovorin combination
RxNorm normalized name: fluorouracil, combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-fluorouracil-leucovorin combination with allopurinol
Trial: 1804386
Drug: 5-fluorouracil-leucovorin combination
RxNorm normalized name: fluorouracil, combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-fluorouracil-leucovorin combination without allopurinol
Trial: 6376916
Drug: 30-g protein-restricted
RxNorm normalized name: pegvisomant
DrugBank: Pegvisomant (DB00082)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 30-g protein-restricted diet supplemented by keto acids
Trial: 31214846
Drug: Three-step yoga
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-step yoga program for T2DM, details on dosage and duration not specified.
Trial: 25116969
Drug: Visible light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Visible light (sham treatment)
Trial: 15035598
Drug: Control (Inhaled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (Inhaled corticosteroid therapy)
Trial: 12453333
Drug: 5-fluorouracil-based chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-fluorouracil-based chemotherapy with radiation
Trial: 11475715
Drug: Buyang Huanwu
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buyang Huanwu Decoction (BHD) combined with western medicine (prednisone acetate and cytoxan)
Trial: 11475715
Drug: Western medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medicine (prednisone acetate and cytoxan) with aspirin and persantin
Trial: 7544731
Drug: Finasteride treatment
RxNorm normalized name: Finasteride
DrugBank: Finasteride (DB01216)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Finasteride treatment for 5 years
Trial: 31112079
Drug: Misoprostol 200
RxNorm normalized name: MISOPROSTOL 200MCG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Misoprostol 200 µg applied vaginally 10 hours and 4 hours prior to IUD insertion
Trial: 31112079
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet applied vaginally 10 hours and 4 hours prior to IUD insertion
Trial: 28319872
Drug: Intrathecal baclofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal baclofen (ITB) bolus injection, 50-μg
Trial: 25878371
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose (500 mg) of IV methylprednisolone
Trial: 25878371
Drug: 10 days
RxNorm normalized name: AlleRx 10-day Dose Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 days of oral prednisolone
Trial: 17005502
Drug: OPTIMISE programme
RxNorm normalized name: PUMP,LUTREPULSE PROGRAMMABLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OPTIMISE programme (treatment group)
Trial: 9863109
Drug: RBUD-1 (a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RBUD-1 (a preparation of Chinese herbal medicine)
Trial: 9863109
Drug: Composite prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Composite prescription of Western and Chinese medicine
Trial: 30457358
Drug: Ferric carboxymaltose
RxNorm normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ferric carboxymaltose treatment
Trial: 24597472
Drug: Idrabiotaparinux (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idrabiotaparinux (3 mg weekly for the first 7 weeks, then 2 mg, adjusted to 1.5 mg for certain patients)
Trial: 24597472
Drug: Warfarin (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (daily with dose adjustment to maintain INR between 2.0 and 3.0)
Trial: 21169087
Drug: PET scan
RxNorm normalized name: Pet Pectillin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PET scan before treatment
Trial: 21169087
Drug: PET scan
RxNorm normalized name: Pet Pectillin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PET scan after 6 months of treatment
Trial: 19932833
Drug: Topical diclofenac
RxNorm normalized name: diclofenac Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical diclofenac sodium 1% gel (DSG) 4 g, applied 4 times daily for 12 weeks
Trial: 19932833
Drug: Vehicle (placebo)
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle (placebo) 4 g, applied 4 times daily for 12 weeks
Trial: 12609785
Drug: LHA formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LHA formulation (2-hydroxy-5-octanoyl benzoic acid), applied twice daily for 2 weeks
Trial: 10338051
Drug: Alkalinized local
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alkalinized local anaesthesia (LA) solution (n = 19)
Trial: 10338051
Drug: Non-alkalinized local
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-alkalinized local anaesthesia (LA) solution (n = 21)
Trial: 10338051
Drug: EMLA cream
RxNorm normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMLA cream with local anaesthesia and patient-controlled analgesia with alfentanil
Trial: 8520498
Drug: Intron A
RxNorm normalized name: Intron A
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intron A (3 mega units/m2 s.c. three times weekly)
Trial: 3551617
Drug: Ketorolac tromethamine
RxNorm normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketorolac tromethamine 0.5% ophthalmic solution
Trial: 7203334
Drug: Neostigmine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine (0.5 mg per single dose)
Trial: 7203334
Drug: Dihydroergotamine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydroergotamine (1 mg)
Trial: 24597650
Drug: RehabMaster intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: RehabMaster intervention plus conventional occupational therapy (10 sessions)
Trial: 24597650
Drug: Conventional occupational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional occupational therapy only (OT-only group)
Trial: 15914127
Drug: St. John's
RxNorm normalized name: St. john's wort
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: St. John's Wort 300 mg three times daily
Trial: 15914127
Drug: Low-dose OC
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose OC (Loestrin 1/20) with placebo
Trial: 12626213
Drug: Low-dose estrogen-progestin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose estrogen-progestin therapy (1 mg 17beta-estradiol with 500 micro g norethisterone acetate daily)
Trial: 10337434
Drug: Patanol (olopatadine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patanol (olopatadine hydrochloride 0.1% ophthalmic solution)
Trial: 10337434
Drug: Claritin (loratadine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Claritin (loratadine, 10 mg tablet)
Trial: 8527539
Drug: Ciprofloxacin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (500 mg daily for 3 days)
Trial: 2736055
Drug: Biosynthetic human
RxNorm normalized name: Proinsulin biosynthetic human
DrugBank: Proinsulin human (DB17875)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biosynthetic human growth hormone (somatropin)
Trial: 24425697
Drug: Emergency medical
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emergency medical services treatment for ACS
Trial: 20417572
Drug: Maintenance group
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance group (optimal therapeutic doses continued throughout the study)
Trial: 20417572
Drug: 26-week group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 26-week group (optimal therapeutic doses continued for 26 weeks, followed by a 50% dose reduction maintained until the end of the study)
Trial: 20417572
Drug: 4-week group
RxNorm normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4-week group (optimal therapeutic doses continued for 4 weeks, followed by a 50% dose reduction maintained until the end of the study)